Office of Clinical Research, Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center, 2520 Elisha Ave,, Zion, IL 60099, USA.
Health Qual Life Outcomes. 2011 Aug 3;9:62. doi: 10.1186/1477-7525-9-62.
Several studies have demonstrated the predictive significance on survival of baseline quality of life (QoL) in colorectal cancer (CRC) with little information on the impact of changes in QoL scores on prognosis in CRC. We investigated whether changes in QoL during treatment could predict survival in CRC.
We evaluated 396 stages III-IV CRC patients available for a minimum follow-up of 3 months. QoL was evaluated at baseline and after 3 months of treatment using EORTC QLQ-C30. Cox regression evaluated the prognostic significance of baseline, 3-month and changes in QoL scores after adjusting for age, gender and stage at diagnosis.
After adjusting for covariates, every 10-point increase in both baseline appetite loss and global QoL score was associated with a 7% increased risk of death with HR = 1.07 (95% CI, 1.01-1.14; P = 0.02) and (HR = 0.93 (95% CI, 0.87-0.98; P = 0.01) respectively. A lower risk of death was associated with a 10-point improvement in physical function at 3 months (HR, 0.86; 95% CI, 0.78-0.94; P = 0.001). Surprisingly, a higher risk of death was associated with a 10-point improvement in social function at 3 months (HR, 1.08; 95% CI, 1.02-1.13; P = 0.008).
This study provides preliminary evidence to indicate that CRC patients whose physical function improves within 3 months of treatment have a significantly increased probability of survival. These findings should be used in clinical practice to systematically address QoL-related problems of CRC patients throughout their treatment course.
多项研究已经证明,在结直肠癌(CRC)中,基线生活质量(QoL)对生存有预测意义,但关于 QoL 评分变化对 CRC 预后的影响的信息较少。我们研究了治疗过程中 QoL 的变化是否可以预测 CRC 的生存。
我们评估了 396 名可进行至少 3 个月随访的 III-IV 期 CRC 患者。在基线和治疗 3 个月时使用 EORTC QLQ-C30 评估 QoL。Cox 回归调整年龄、性别和诊断时的分期后,评估基线、3 个月时和治疗后 QoL 评分变化的预后意义。
调整了协变量后,基线食欲丧失和总体 QoL 评分每增加 10 分,死亡风险分别增加 7%(HR = 1.07,95%CI,1.01-1.14;P = 0.02)和(HR = 0.93,95%CI,0.87-0.98;P = 0.01)。3 个月时身体功能改善 10 分与死亡风险降低相关(HR,0.86;95%CI,0.78-0.94;P = 0.001)。令人惊讶的是,3 个月时社会功能改善 10 分与死亡风险增加相关(HR,1.08;95%CI,1.02-1.13;P = 0.008)。
本研究初步表明,在治疗后 3 个月内身体功能改善的 CRC 患者的生存概率显著增加。这些发现应在临床实践中使用,以系统地解决 CRC 患者在整个治疗过程中的 QoL 相关问题。